SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike is drawing attention amid a cybersecurity-sector selloff, with traders linking the pressure largely to Fortinets earnings reaction and broader weakness in software stocks. Some see the drop as sympathy selling and a buying opportunity, while others argue CRWDs rich valuation leaves it vulnerable to further declines.

Tidal Trust II - YieldMax Semiconductor Portfolio Option Income ETF

YieldMax Semiconductor Portfolio Option Income ETF

CHPY is drawing attention amid a sharp pullback across semiconductor and AI-related stocks, which traders attribute to de-risking and concerns about AI valuations and spending. Some holders are buying the dip and focusing on long-term chip demand and weekly income, while skeptics worry about further losses, declining distributions, and NAV erosion.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. The firm focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgans quarterly results missed expectations, with weaker fixed-income trading and securities losses weighing on the report; stronger net interest income and lending provided an offset. Traders are debating the stocks resilient, volatile reaction despite the earnings miss.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios post-earnings selloff is centered on a softer fourth-quarter organic-growth outlook, which traders see as a deceleration despite the quarterly beat and raised full-year guidance. The community is divided between waiting for support after the sharp drop and viewing the weaker outlook and slowing messaging growth as reasons to stay cautious.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is drawing attention amid a prolonged selloff and fresh lows, with traders citing Chinese EV weakness, analyst downgrades, and concerns about demand, profitability, and upcoming delivery guidance. Bulls point to rising deliveries, exports, and technology initiatives, but debate why those developments have not supported the share price.

Palo Alto Networks, is a cybersecurity company that provides cybersecurity platforms and services to enterprises, organizations, service providers, and government entities. Its offerings include network and AI security, cloud security, security operations, and identity security solutions. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto is under pressure alongside other cybersecurity stocks after Fortinets weaker service-revenue outlook sparked sector-wide sympathy selling, despite its stronger results elsewhere. Traders debate whether the pullback is overdone given PANWs recurring-security business, while others point to elevated valuations and growth concerns.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Brazilian approval of Transoceans Valaris merger has traders focused on the deals expected scale and synergies, while elevated short interest is fueling squeeze speculation. Recent offshore contract wins and higher day rates bolster the bullish case, but some traders remain concerned about share dilution, debt and the stocks muted response to positive developments.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

UCO is drawing attention amid sharp crude-oil swings tied to U.S.-Iran tensions, Strait of Hormuz supply concerns, and shifting reports about a possible deal. Traders are divided between bullish bets on continued disruption and expectations of an oil pullback if tensions ease, with some also flagging the risks of trading a leveraged fund in volatile markets.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

Discussion centers on volatile broad-market moves and the Dows relative strength versus tech-heavy indexes, with traders debating whether the rotation into blue chips can persist or signals wider weakness. Rising Treasury yields, Fed policy uncertainty, and Iran-related oil concerns are recurring macro risks, while bullish and crash-focused views remain sharply divided.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novos upcoming Q3 report is the main focus, with traders watching whether oral Wegovy demand and guidance can support a recovery amid competition from Eli Lilly. Bulls anticipate stronger results and see the pills prescription momentum as a positive, while skeptics point to market-share pressure, management concerns, and the stocks prolonged weakness.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Huge Narratives and Market Moments

The Market is once again producing the kind of outsized news that can quickly turn obscure names into market-watchlist favorites. Kraig Biocraft Laboratories (OTCQB:KBLB), HCW Biologics (NASDAQ:HCWB), Uxin (NASDAQ:UXIN), Green Circle Decarbonize Technology (NYSEAMERICAN:GCDT), Powell Max Limited (NASDAQ: PMAX), Netcapital (NASDAQ:NCPL), STAK Inc. (NASDAQ:STAK), and Wetour Robotics (NASDAQ:WETO) are each tied to different narratives.

HCW Biologics Commences 1-for-6 Reverse Stock Split

(RTTNews) - HCW Biologics Inc. (HCWB), a clinical-stage biopharmaceutical company, Friday announced that it has been approved for a 1-for-6 reverse stock split of the company's common stock, with par value of $0.0001, effective June 30...

Microcap HCW Biologics' Therapy Shows Early Promise Against Autoimmune Hair Loss

HCW Biologics reports positive Phase 1 data for HCW9302, with all 2nd-cohort alopecia patients showing a clinical response.read more...

Why Is HCW Biologics Stock Surging On Friday?

HCW Biologics Inc. (NASDAQ: HCWB) stock rallies on Friday as a $4 million private placement offering boosts liquidity for its clinical trials.read more...

This Emerging Biotech Wave Could Create the Next Monster Healthcare Winners

The biotechnology sector continues attracting speculative capital as investors aggressively position around next-generation oncology, metabolic disease, and CNS therapy platforms. Artificial intelligence, precision medicine, RNA biology, and novel drug delivery technologies are rapidly reshaping how Wall Street evaluates emerging healthcare companies. As larger pharmaceutical companies race to secure pipeline assets and differentiated platforms, smaller clinical-stage companies with compelling preclinical or clinical data are increasingly finding themselves under the spotlight. $AKTX, $NTHI, $MTVA, $HCWB, $BAC, $STT, $BCS

Why HCW Biologics Stock Is Surging On Thursday?

HCW Biologics Inc. (NASDAQ:HCWB) stock is rallying after securing a $4 million private placement to fund its clinical pipeline. Read the full market breakdown.read more...

Biotech and Biologics Break Out: These Tiny Stocks Are Suddenly Dominating the Market Conversation

Emerging biotech and biologics names exploded onto traders’ radar Wednesday as a wave of clinical milestones, regulatory momentum, strategic acquisitions, and high-volume technical breakouts fueled aggressive speculation across the sector. $HCWB, $TGNT, $KBLB, $SLS, $RKDA, $ROIV, $SLXN

Why HCW Biologics Stock Is Falling On Tuesday?

HCW Biologics Inc. (NASDAQ: HCWB) stock falls on Tuesday. Retail traders lock in gains after a 262% surge driven by Q1 earnings and pipeline updates.read more...

What's Going On With HCW Biologics Stock Monday?

HCW Biologics (HCWB) reports Q1 EPS of $0.37 and $6.54M in sales. Find out why the stock skyrocketed and what's next.read more...

Clinical-Stage Biopharma Surges on Profit Swing and Imminent Phase 1 Data Readout

The market for autoimmune disease therapies is being reshaped by a new generation of biologics targeting regulatory T cells, the immune system's own braking mechanism. Alopecia areata, an autoimmune disorder that causes patchy or complete hair loss, affects millions worldwide and has only recently received its first FDA-approved oral therapies, each carrying significant tolerability concerns. Developers chasing safer, more selective alternatives have made Treg-expanding approaches one of the most closely watched corners of clinical-stage immunology.Shares of HCW Biologics Inc. (Nasdaq: ...

• Reported GAAP EPS of -$11.58 up 71.58% YoY
• Reported revenue of $0.14M up 1969.74% YoY

HCW Biologics faces substantial going concern risks, significantly increased quarterly net losses, and operational difficulties in manufacturing reagents for the CAR-T therapy market that may impede future business growth.

HCW Biologics demonstrated preliminary clinical efficacy for its lead autoimmune candidate, re-acquired commercial-ready reagent rights to support future partnerships, and remains on track for upcoming T-cell engager clinical trials.

HCW Biologics Inc. is a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases. The firm considers age-related low-grade chronic inflammation as a contributing factor to several chronic diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune diseases. The company was founded by Hing C. Wong on April 2, 2018 and is headquartered in Miramar, FL.

HCW Biologics Inc

HCWB Stock Soars Pre-Market On Positive Research Results For CAR-T Cell Therapy

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>HCW Biologics stated that CAR-T cells manufactured with HCW9206 were significantly superior to those manufactured with standard methods.</li><li>The company said that CAR-Ts produced with its reagent are highly enriched in long-lived T memory stem cells.</li><li>HCW Biologics added that these CAR-Ts also displayed potent activity across distinct disease experimental models, namely, HIV-1 or B-cell leukemia.</li></ul>HCW Biologics Inc. (HCWB) shares soared more than 56% in Monday’s pre-market trade after the company announced positive research results for its CAR-T cell therapy.HCW Biologics stated that HCW9206, its proprietary, commercial-stage multi-cytokine fusion protein reagent, provides a new approach to generate CAR-T cells for immunotherapy with increased function at a cost-effective price.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/HCWB">HCW Biologics</a> trended in the ‘bullish’ territory with message volumes at ‘high’ levels.<h2 class="st-heading-2">HCW9206 CAR-Ts Outperform Standard Methods, Says Company</h2>HCW Biologics stated that CAR-T cells manufactured with HCW9206 were significantly superior to those manufactured with standard methods.The company said that CAR-Ts produced using its reagent are highly enriched in long-lived T-memory stem cells. HCW Biologics added that these CAR-Ts also displayed potent activity across distinct disease experimental models, namely, HIV-1 or B-cell leukemia.“Based on experimental models, HCW9206 has shown improvement in functional activities and persistence of CAR-Ts following adoptive transfer, a goal the industry has been trying to achieve for the last decade,” said HCW Biologics CEO, Dr. Hing C. Wong.The company stated that in its study, HCW9206 helped generate long-lasting duoCAR-T cells that showed strong HIV suppression in humanized mouse models using T cells from people living with HIV. The approach could extend CAR-T therapy durability and support efforts toward a functional HIV cure, it added.<h2 class="st-heading-2">Why Are CAR-T Cells Important?</h2>CAR-T cells represent a new way to treat cancer using the patient’s own immune system. These cells genetically modify a patient’s T cells so they can recognize and attack specific cancer cells, reducing damage to healthy tissue compared with traditional treatments.Additionally, once CAR-T cells are modified and infused into a patient’s body, they multiply and continue to fight cancer.<a href="https://stocktwits.com/symbol/HCWB">HCWB stock</a> is down 47% year-to-date and 96% over the past 12 months. The Vanguard Extended Market Index Fund ETF Shares (VXF) is up 20% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/soc-stock-soars-after-sable-resumes-oil-flow-from-california-pipeline/cZ32wB1RIfi">SOC Stock Rises Pre-Market After Energy Secretary Order Restarts Sable’s California Oil Pipeline</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

HCW Biologics said its proprietary multi-cytokine fusion protein reagent, HCW9206, offers a cost-effective way to generate higher-function CAR-T cells for immunotherapy.

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$HCWB HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors

Jayson Tucker

Day Trader

$HCWB what a load of shit this company is. It is blantantly a ching chang chinese siphoning scam for the ccp.

Donald J Dumps

$HCWB HCW Biologics kept its IND filing timeline for HCW11-018b on track for 1H 2027, targeting a first-in-human solid-tumor study.
A recent FDA Type B meeting provided guidance on remaining steps to support the IND package.
Clinical-grade cGMP manufacturing is underway for trial supply.
HCW11-018b combines a tissue factor-targeting, CD3-engaging BiTE design with IL-15 signaling and a TGF-β trap to counter tumor immunosuppression.

Joe_088

$HCWB For the one-year price torecasts, the average price target is 48.00 with a high estimate of 48.00 and a low estimate of 48.00.
Updated on 10/02/2026

Feed

News

Sentiment

Earnings

Fundamentals

Info

HCWB HCW Biologics Inc

Fundamentals

Latest HCWB News